OLAPARIB IN COMBINATION WITH ABIRATERONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A SYSTEMATIC REVIEW
Palavras-chave:
Metastatic Castration-Resistant Prostate Cancer, Antineoplastic Protocols, Olaparib, AbirateroneResumo
Metastatic castration-resistant prostate cancer (mCRPC) is characterized by high levels of prostate-specific antigen even in scenarios with serum testosterone levels lower than those of castration. Thus, it consists of a tumor progression resistant to androgen blockade therapy. In this context, the objective of this study is to evaluate the efficacy and tolerability of Olaparib in combination with Abiraterone compared to placebo plus Abiraterone in patients with mCRPC. This work is a systematic literature review, whose data were obtained from the search for primary studies in the Embase, Medline, Lilacs, Cochrane Central Register of Controlled Trials, and PubMed databases. The search was based on the use of the following health descriptors in English: "Castration-Resistant Prostatic Neoplasms"; "Drug Therapy"; "Abiraterone Acetate" and "Olaparib". The obtained results evidenced that the use of Olaparib in monotherapy or in association with Abiraterone demonstrated significant benefits in progression-free survival and overall survival in patients with mCRPC harboring BRCA1, BRCA2, and ATM mutations whose disease had progressed with a next-generation hormonal agent. This same benefit was also observed in the general trial population with alterations in homologous recombination repair genes. Therefore, it is concluded that this combination results in a combined antitumor effect, which implies a better quality of life for the patient under treatment, optimizing pain relief and any other complications inherent to a metastatic disease requiring palliative therapy.
Referências
ABIDA, Wassim & ANTONARAKIS, Emmanuel S. et al. Management of advanced prostate cancer with germline or somatic homologous recombination repair deficiency. UpToDate. 2024.
CHAKRAVARTY, Debyani et al. Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion. Journal of Clinical Oncology, v. 40, n. 11, p. 1231-1258, 2022.
CLARKE, Noel W. et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM evidence, v. 1, n. 9, p. EVIDoa2200043, 2022.
CLARKE, Noel W. et al. Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC). 2023.
DAWSON, Nancy A. et al. Overview of the treatment of castration-resistant prostate cancer (CRPC). UpToDate. 2024.
DE BONO, J. S. et al. Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from> 4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study. Annals of Oncology, v. 30, p. v328-v329, 2019.
DE BONO, J. S. et al. Olaparib for metastatic castration-resistant prostate cancer. New England Journal of Medicine, v. 382, n. 22, p. 2091-2102, 2020.
ROUBAUD, Guilhem et al. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. European Journal of Cancer, v. 170, p. 73-84, 2022.
THIERY-VUILLEMIN, Antoine et al. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. The Lancet Oncology, v. 23, n. 3, p. 393-405, 2022.
